| scholarly article | Q13442814 |
| P50 | author | Ahmed K Alomari | Q38801917 |
| P2093 | author name string | Alexander O Vortmeyer | |
| Harriet M Kluger | |||
| Justine V Cohen | |||
| Lucia B Jilaveanu | |||
| Veronica L Chiang | |||
| Amit Mahajan | |||
| Sarah B Goldberg | |||
| P2860 | cites work | Ipilimumab in a Phase II trial of melanoma patients with brain metastases | Q41274844 |
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Delayed radiation-induced vasculitic leukoencephalopathy | Q44677201 | ||
| Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. | Q45409658 | ||
| Significance of histology in determining management of lesions regrowing after radiosurgery | Q46279516 | ||
| CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. | Q46456759 | ||
| Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases | Q48109035 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases | Q48868052 | ||
| Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle | Q21195861 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 | ||
| Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study | Q33361043 | ||
| Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. | Q33386298 | ||
| Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial | Q33402830 | ||
| Determinants of survival in patients with brain metastases from cutaneous melanoma | Q33794890 | ||
| Trafficking of immune cells in the central nervous system | Q33815795 | ||
| Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery | Q35032280 | ||
| Melanoma brain metastases: is it time to reassess the bias? | Q35214698 | ||
| Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases | Q37480713 | ||
| Ipilimumab and radiation therapy for melanoma brain metastases | Q37481186 | ||
| Diagnosis and treatment of melanoma brain metastasis: a literature review | Q37531863 | ||
| Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival | Q38019011 | ||
| Determinants of outcome in melanoma patients with cerebral metastases | Q38517839 | ||
| P433 | issue | 3 | |
| P921 | main subject | brain metastasis | Q1620196 |
| pembrolizumab | Q13896859 | ||
| P304 | page(s) | 179-182 | |
| P577 | publication date | 2015-12-23 | |
| P1433 | published in | Cancer Immunology Research | Q26841983 |
| P1476 | title | Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment | |
| P478 | volume | 4 |
| Q97543103 | A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria |
| Q92563188 | Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases |
| Q55206910 | An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. |
| Q37584395 | Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives |
| Q91099817 | Brain metastases |
| Q47879878 | Brain metastases: neuroimaging |
| Q39331752 | Challenges in the delivery of therapies to melanoma brain metastases |
| Q90216774 | Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors |
| Q47205132 | Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. |
| Q90436833 | Complications associated with immunotherapy for brain metastases |
| Q49871985 | Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
| Q92604963 | Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology |
| Q30234702 | Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. |
| Q48225182 | Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer |
| Q39069273 | Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. |
| Q50422388 | Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma |
| Q94006521 | Highlights from the Literature |
| Q91712013 | How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors? |
| Q38752191 | Immunotherapy and radiation in glioblastoma. |
| Q45042328 | Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma |
| Q58582837 | Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial |
| Q57062843 | Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment |
| Q39312420 | MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. |
| Q64971747 | Management of metastatic cutaneous melanoma: updates in clinical practice. |
| Q38766796 | Melanoma Brain Metastases: Current Areas of Investigation and Future Directions |
| Q42547688 | Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment |
| Q38807942 | Melanoma central nervous system metastases: current approaches, challenges, and opportunities |
| Q38930084 | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| Q49715942 | Oncologie dermatologique : mélanome avancé, effets secondaires des anti-PD1, place de la monothérapie en première ligne, traitement du mélanome métastatique |
| Q33926135 | Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial |
| Q39190201 | Pembrolizumab use for the treatment of advanced melanoma |
| Q39632681 | Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors |
| Q90172203 | Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma |
| Q59132343 | Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors |
| Q55516526 | Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment☆☆☆. |
| Q58563207 | Pseudoprogression of Melanoma Brain Metastases |
| Q58608684 | Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study |
| Q58758291 | Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment |
| Q38857040 | Targeted Therapies for Melanoma Brain Metastases |
| Q51742545 | Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. |
| Q38909389 | The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma |
| Q89018078 | The Utility of Liquid Biopsy in Central Nervous System Malignancies |
| Q92463703 | The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy |
| Q90600121 | The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors |
| Q90216752 | Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer |
Search more.